Description The purpose of this clinical practice update is to evaluate the evidence
describing the interaction between direct-acting antiviral (DAA) therapy for hepatitis and …

Interferon (IFN)-free regimen using new direct acting antiviral (DAA) is a revolution for the
treatment of patients with chronic hepatitis C. More than 95% of patients have a sustained …

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver
cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been …

Direct-acting antivirals (DAAs) induce a rapid virologic response (SVR) in up to 99% of
chronic hepatitis C patients. The role of SVR by DAAs on the incidence or recurrence of …

Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects
millions of people worldwide and is associated with cancer. Direct‐acting antivirals (DAAs) …

Traditionally, the progression from compensated to decompensated cirrhosis has been
regarded as a point of no return in the natural history of the disease. However, this point of …

The current approaches to the management of patients with decompensated cirrhosis are
based on targeted strategies aimed at preventing or treating specific complications of the …

Conclusions: After TIPS implantation, mortality is increased by aging, but TIPS placement
should not be precluded in patients older than 70 years. In older adults, creatinine and …

Whether direct‐acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC)
recurrence after tumor‐directed therapy is controversial. We sought to determine the impact …

Background: Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its
complications. Viral eradication is essential to prevent disease progression and reduces …